Guggenheim Initiates Coverage On Generate Biomedicines with Buy Rating, Announces Price Target of $30
Benzinga Newsdesk 7 months ago
NewsPrice TargetInitiationAnalyst Ratings
Guggenheim analyst Seamus Fernandez initiates coverage on Generate Biomedicines (NASDAQ:GENB) with a Buy rating and announces Price Target of $30.
Guggenheim analyst Seamus Fernandez initiates coverage on Generate Biomedicines (NASDAQ:GENB) with a Buy rating and announces Price Target of $30.